Koon Yan "Chris" Pak, Ph.D.

Chief Executive Officer and Chairman of the Board

Dr. Chris Pak brings three decades of experience in the biopharmaceutical industry. Chris was formerly with Centocor, now a subsidiary of Johnson and Johnson, where he invented and developed novel radiopharmaceuticals and participated in the filing of twenty IND applications for cancer and cardiovascular diseases. He has founded and led multiple societies promoting Nuclear Medicine and Molecular Imaging and entrepreneurship organizations.

Dr. Pak has published more than ninety articles and holds numerous patents on therapeutics and diagnostics. His awards include the 2019 Ernst & Young Entrepreneur of the Year Finalist of Greater Philadelphia, Asian Chamber of Commerce Outstanding Asian American Business Award, Ben Franklin Emerging Business Award, State University of New York Alumni Honor Roll, and the 2014 Lifetime Achievement Award from the Chinese American Society of Nuclear Medicine and Molecular Imaging.

Ji Li, Ph.D.

Board Director

An accomplished business creator, Dr. Li has orchestrated investment in and headed multiple life science businesses. In addition to his role as COO at MTTI, Dr. Li is President & CEO and co-founder of UFOVAX, Inc. commercializing Scripps Institute’s one component, self-assembling protein nanoparticle (1c-SApNP) vaccine platform technology generating promising candidates for HIV, HCV, Ebola, RSV, MERS and, most recently, COVID-19.

Following his earlier tenure as VP R&D of Rhodia Asia Pacific he became Managing Director, M&A, Technology Development and Pharmaceutical Division and later Group President & CEO for the Feixiang Group. He continues as a Principal in Comway Capital and serves as Board Director of several Biotech startup companies

Jeffrey A. Mattis, Ph.D.

Senior Vice President of Scientific & Regulatory Affairs, Board Director

Dr. Mattis is a biopharmaceutical executive with more than 30 years’ experience in the technical development of biopharmaceuticals. Dr. Mattis previously served as Vice President of Pharmaceutical Development for Centocor. Dr. Mattis was instrumental in the technical development of several biopharmaceuticals approved for the US and multinational markets. These include ReoPro®, an anti-platelet drug for use in coronary angioplasty; Remicade®, a drug for treatment of Crohn’s disease and rheumatoid arthritis; and Myoscint®, a cardiac imaging agent.

Dr. Peter E. Grebow, Ph.D.

Board Director

Founder and President of P.E. Grebow Consulting, Inc. since 2011. Dr. Grebow has more than twenty-five years of experience in the pharmaceutical industry, last serving as an EVP of Research & Development of Eagle Pharmaceuticals Inc.

Earlier Dr. Grebow held senior executive roles with Cephalon, Inc.; EVP Worldwide Technical Operations, EVP of Cephalon Ventures and EVP of Worldwide Technical Operations of Cima Labs Inc. EVP of at Cephalon, Inc. Peter also served as VP of Drug Development for Rorer Central Research, a division of Rhone-Poulenc Rorer Pharmaceuticals Inc.

He serves/has served as a Director of Inspyr Therapeutics, Inc. (Chair), Complexa, Inc., Q Therapeutics, Inc., Optimer Pharmaceuticals, Inc. and Harrington Discovery Institute

Sean Wang

Founder & CEO, B&W TEK, Board Director

An accomplished entrepreneur, inventor, scientist and engineer Dr. Wang has launched, incubated, and financed more than a dozen companies, most of them based on the generation, manipulation, and detection of light.

He is CEO of B&W TEK Inc, a leading photonic instrument company producing analytical instrumentation, medical systems and lasers, recently acquired by Metrohm Group, together becoming one of the largest solutions-providers for mobile spectroscopy.

Sean holds advanced degrees in Physics and Electrical Engineering. He is the author of many scientific publications and holds 60 US and international patents, received or filed. He is a fellow of the American Society of Laser Medicine and Surgery. Recently named Entrepreneur in Residence with multiple honors for innovation, Dr. Wang is an adjunct professor and a member of the advisory council at the University of Delaware. He is founding Director of the PBM Institute and Co-founder and Chairman of LiteCure, both focused on innovations in Photonic Based Medicine at the UD STAR Campus.

Professor Richard Wahl, M.D., FACR

Professor of Radiology and Radiation Oncology Washington University in St Louis School of Medicine

Professor Wahl is a Professor of radiology and radiation oncology at Washington University School of Medicine in St. Louis. From 2014-2023 he served as the Elizabeth E. Mallinckrodt Professor and Chair of the Department of Radiology and Director of the Mallinckrodt Institute of Radiology at Washington University School of Medicine in St Louis. He served from 2000-2014 as the inaugural Henry N. Wagner, Jr. Professor of Nuclear Medicine and director of nuclear medicine at Johns Hopkins University School of Medicine in St. Louis. Prior to that he served as a professor at the University of Michigan in Ann Arbor, MI. Professor Wahl is recognized as a world leader in the field of targeted radiopharmaceuticals for diagnosing and treating cancer. With an emphasis on PET and multi-modality imaging, such as PET-CT, his work enables precision diagnosis of a broad array of human cancers and other serious diseases. Professor Wahl is one of the inventors of radio-immunotherapy of lymphoma, which is a combination of radiotherapy and immunotherapy that facilitates targeted treatments. He has also been an inventor of a number of FDA approved medical devices, such as radionuclide guided biopsy. Professor Wahl holds 18 radiology patents and has published more than 500 peer-reviewed scientific papers and several books. He has served as a chairman of the American Board of Nuclear Medicine (ABNM), president of the Institute for Clinical PET (ICP) program, refresher course chair for Radiological Society of North America and on multiple NIH study sections. He was elected as a member of the US National Academy of Medicine in 2015. More recently, Professor Wahl served as 2021-22 president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and founded the Mars Shot for Nuclear Medicine initiative. He has received multiple professional awards including the Hounsfield, Saul Hertz, Tetalman, Berson-Yalow and deHevesy awards and the 2023 Washington University Alumni Association achievement award. He remains actively engaged in clinical and research applications of radiotheranostics.

Steven Brem, MD.

Chief of Neurosurgical Oncology, Co-director of Penn Brain Tumor Center and Professor of Neurosurgery at University of Pennsylvania, Perelman School of Medicine.

Dr. Brem is a renowned clinical research scientist who sits on the scientific/medical advisory boards of several cancer research associations including American Association of Cancer Research, American Brain Tumor Association and Brain Tumor Action Network among others. Dr. Brem has extensive clinical research experience in many types of tumors. He has reviewed and approved 127 tumor trial protocols in University of Pennsylvania and at Moffitt Cancer Center. Dr. Brem is currently the principle investigator of six cancer trials, including two NIH funded and four industry sponsored trials. He has published more than 100 clinical research articles in peer-reviewed journals and presented more than 100 posters in medical conferences such as ASCO (American Society of Clinical Oncology).

Daniel Pryma, MD

Gerd Muehllehner Professor of Radiology, Chief of the Division of Nuclear Medicine Imaging and Therapy at the Perelman School of Medicine at the University of Pennsylvania

Daniel Pryma, MD is the Gerd Muehllehner Professor of Radiology, Chief of the Division of Nuclear Medicine Imaging and Therapy at the Perelman School of Medicine at the University of Pennsylvania and the Associate Director for Clinical Research at the Abramson Cancer Center of the University of Pennsylvania. He also serves as Chair of the Imaging Committee for NRG Oncology. Dr. Pryma’s primary research interests are in therapeutic radiopharmaceuticals, particularly alpha particle emitters, and companion diagnostics for both solid and liquid cancers. He directs a pre-clinical radiopharmaceutical laboratory in addition to his extensive work in clinical trials spanning from first in human through registrational and post-registrational trials. He is engaged in multiple clinical programs: Neuroendocrine Tumor Program, Endocrine Tumor Program and Genitourinary Tumor Program. He graduated with honors from Loyola University of Chicago, Stritch School Of Medicine in 2002 and completed his medical training at Memorial Sloan-Kettering Cancer Center having been board certified in Nuclear Medicine in 2005. Dr. Pryma has 129 publications in clinical practice, PET, PET/CT, Radiopharmaceutical Therapy, Radioimmunotherapy and Nuclear Oncology.